SCHEMBL2164157

SCHEMBL2164157

Nc1nc(N)c2c(N3CCN(C(=O)c4ccc(F)cc4)CC3)cccc2n1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.50
ABL1 P00519 1/20 0.47
BCR P11274 1/20 0.47
SLC6A7 Q99884 2/20 0.47
KDM4E B2RXH2 3/20 0.46
ALOX15 P16050 1/20 0.46
DCPS Q96C86 2/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
HTT P42858 2/20 0.45
MAPK1 P28482 2/20 0.45
LMNA P02545 1/20 0.45
TSHR P16473 1/20 0.45
HSP90AA1 P07900 1/20 0.44
ALDH1A1 P00352 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HSD17B10 Q99714 1/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2166325 0.90 KDM4E (0.52) KDM4EALOX15DCPSMEN1KMT2A
SCHEMBL2166066 0.89 ALDH1A1 (0.51) ABL1BCRSLC6A7KDM4EDCPS
SCHEMBL2166122 0.89 MEN1 (0.52) L3MBTL1ABL1BCRSLC6A7KDM4E
SCHEMBL2168162 0.85 LMNA (0.54) ALOX15DCPSMEN1KMT2ASMN1; SMN2
SCHEMBL2165448 0.84 HPGD (0.47) L3MBTL1DCPSMEN1KMT2ASMN1; SMN2
SCHEMBL2166586 0.83 SMN1; SMN2 (0.55) L3MBTL1KDM4EALOX15MEN1KMT2A
SCHEMBL2165366 0.83 SMN1; SMN2 (0.51) L3MBTL1KDM4EALOX15MEN1KMT2A
SCHEMBL2168221 0.83 HPGD (0.51) ABL1BCRKDM4EDCPSMEN1
SCHEMBL2166078 0.82 ALDH1A1 (0.58) KDM4EKMT2ASMN1; SMN2LMNATSHR
SCHEMBL2166596 0.79 USP2 (0.60) KDM4EMEN1KMT2ASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2069316-B1 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY FAMILIES OF SPINAL MUSCULAR ATROPHY (US) 2015-10-07 EP disclosed
EP-2615086-A1 2,4-Diaminoquinazolines for the treatment of spinal muscular atrophy Families of Spinal Muscular Atrophy (US) 2013-07-17 EP disclosed
US-7985755-B2 2,4-diaminoquinazolines for spinal muscular atrophy FAMILIES OF SPINAL MUSCULAR ATROPHY (US) 2011-07-26 US disclosed
US-20090042900-A1 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY DECODE CHEMISTRY, INC. (US) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042900-A1 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY SMN1; SMN2, MUSK, MYT1 L3MBTL1 2158/4885ABL1 1742/4885BCR 3826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.